Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism (REVERSEII)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00967304|
Recruitment Status : Completed
First Posted : August 27, 2009
Last Update Posted : September 1, 2016
|Condition or disease||Intervention/treatment||Phase|
|Idiopathic Venous Thromboembolism||Other: Application of the"Men continue and HER DOO2" rule||Phase 4|
Up to 50% of patients with a first episode of venous thromboembolism (VTE) have no identifiable cause (i.e. are unprovoked VTEs). The risk of recurrent VTE in this large group of patients with unprovoked VTE after 3-6 months of anticoagulant therapy is 5-10.8% in the year following discontinuation of oral anticoagulant therapy. One in six to one in twenty recurrences of a new VTE are fatal. Given the intermediate risks of recurrence in unselected unprovoked VTE patients, clinicians do not have clear guidance on whether to continue or discontinue anticoagulants in patients with unprovoked VTE. Recently attention has turned to the concept of risk stratification to identify subgroups of patients with unprovoked VTE who could safely discontinue oral anticoagulation therapy (OAT).
In the REVERSE I study, a clinical decision rule derivation study conducted from 2001 to 2006, we developed and internally validated the clinical decision rule "Men continue and HER DOO2" that identifies patients with a first unprovoked VTE who likely have a low risk of recurrent VTE and could safely discontinue OAT subsequent to 5-7 months of OAT. The present study will evaluate if the "Men continue and HER DOO2" rule (comprised of gender, elevated D-dimer levels, post-thrombotic signs, obesity, and older age) is safe, clinically useful, and reproducible when prospectively implemented in multiple centers and a variety of settings. If this clinical decision rule is validated, it will provide physicians with important information to allow them to more confidently identify unprovoked VTE patients at low risk of VTE recurrence who may not need to continue OAT.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2779 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||REVERSEII: Validation of the "Men and HERDOO2"- A Clinical Decision Rule to Identify Patients With "Unprovoked" Venous Thromboembolism Who Can Discontinue Anticoagulants After 6 Months of Treatment.|
|Study Start Date :||November 2008|
|Actual Primary Completion Date :||January 2015|
|Actual Study Completion Date :||July 2016|
Experimental: 1 Discontinue OAT or AAA
Patients classified as being at low risk of recurrent VTE by the "HER DOO2"rule.
If the clinical decision rule indicates that a patient is at low recurrence risk (<3% per year); anticoagulant therapy will be withdrawn and the participant will then be followed for 1 year for any VTE recurrence and/or bleeding.
Other: Application of the"Men continue and HER DOO2" rule
Consecutive patients will have the"Men continue and HER DOO2" rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.
"Men continue and HER DOO2" rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years.
Other Name: Clinical Decision Rule
No Intervention: 2 Observation arm
Men and patients classified as being at high risk of recurrent VTE by the "HER DOO2"rule.
If the clinical decision rule indicates that a patient is at high recurrence risk then the decision to continue or discontinue anticoagulant therapy will be left to the discretion of physicians and patients as per current standard of care and this decision recorded. High risk patients (females classified as being at high risk of recurrent VTE by the CDR, and all males) will then be followed as an observational cohort for 1 year for any VTE recurrence and/or bleeding.
- The primary study outcome is the incidence of adjudicated recurrent major VTE at 1 year in patients deemed by the "Men and HER DOO2" CDR to be at low risk of recurrent VTE. [ Time Frame: One year ]
- Any VTE 1 year event rate in low risk patients [ Time Frame: One year ]
- Major bleeding 1 year event rate in un-anticoagulated low risk patients [ Time Frame: One year ]
- Major VTE 1 year event rate in high risk patients who continue anticoagulant therapy [ Time Frame: One year ]
- Major VTE 1 year event rate in high risk patients who discontinue anticoagulant therapy [ Time Frame: One year ]
- Major Bleeding 1 year event rate in high risk patients [ Time Frame: One year ]
- Clinical utility of the rule [ Time Frame: One year ]
- Inter-observer reliability of the clinical decision rule [ Time Frame: One year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00967304
|Study Chair:||Marc Rodger, MD, MSc||Ottawa Hospital Research Institute|